The association between factor V Leiden, MTHFR C667t/A1298c polymorphisms and pregnancy outcomes

The present study aims to characterize the association between factor V Leiden, MTHFR C667T/A1298C polymo rphisms and adverse pregnancy outcomes such as early recurrent pregnancy loss, thrombotic complications, fetal growth restriction, pre-eclamsia.Material and methods: We aimed to retrospectively assess the pregnancy outcomes of patients with factor V Leiden, MTHFR C667T/A1298C polymorphisms and their combination, between September 2019 and October 2020.Was determined the activity of protein C, antithrombin III and protein S activity .After isolation of blood DNA was evaluated Factor V Leiden, and MTHFR C667T/A1298C polymorphisms.Results: We segregated the 179 patients into 7 groups as follows: factor V Leiden mutation heterozygote and homozygote groups, patients with both factor V Leiden and MTHFR mutations, MTHFR A1298C polymorphism homozygote and heterozygote groups, and MTHFR C667T polymorphism homozygote and heterozygote groups.Although higher IVF rates were identified in the MTHFR C667T heterozygote group (23.9%) and in the FVL-homozygote group (33.3%), no statistically significant difference was calculated.Recurrent pregnancy losses were more frequently encountered in the FVL homozygote and FVL-MTHFR groups (66.6% and 66.7%), and we found a significant association between this parameter and patients with factor V Leiden and a combination of factor V Leiden -MTHFR polymorphisms (p<0.05).Conclusions: Our results suggest a strong association between factor V Leiden polymorphism, or between the combination of factor V Leiden and MTHFR polymorphism with adverse pregnancy outcomes such as thrombotic complications, early recurrent pregnancy loss and intrauterine growth restriction.